Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech deals
Biotech
US VC launches another biotech with China-licensed asset
Aditum is offering up to $1 billion biobucks to Mabwell for exclusive global licensing rights to a dual-target siRNA candidate.
Gabrielle Masson
Sep 17, 2025 10:30am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Braveheart pays $65M to challenge BMS for heart disease market
Sep 5, 2025 9:05am
China-based Novatim notches new deal with another US biotech
Sep 2, 2025 2:36pm
Vertex boosts artillery with $2B-plus Enlaza pact
Sep 2, 2025 10:26am
